Biologic Specimen and Data Repository Information Coordinating Center
Home > Studies > BARI

Resources Available

Study Datasets Only

Study Documents

PDF Data Dictionary (PDF - 36.1 KB)
PDF Protocol (PDF - 5.4 MB)

Persons using assistive technology may not be able to fully access information in the study documents. For assistance, Contact BioLINCC and include the web address and/or publication title in your message.

If you need help accessing information in different file formats such as PDF, XLS, DOC, see Instructions for Downloading Viewers and Players.

Bypass Angioplasty Revascularization Investigation (BARI)

Clinical Trials URL: http://www.clinicaltrials.gov/ct/sh...
Study Type: Clinical Trial
Prepared on October 13, 2008
Last Updated on June 23, 2005
Study Dates: 1987-2004
Consent: Unrestricted Consent
Commercial Use Restrictions: No
NHLBI Division: DCVS
Collection Type: Open BioLINCC Study - See bottom of this webpage for request information

Objectives

The BARI (Bypass Angioplasty Revascularization Investigation) trial was designed to compare survival in patients randomized to receive either percutaneous transluminal coronary balloon angioplasty (PTCA) or coronary artery bypass grafting (CABG).

Background

Angioplasty and bypass surgery have been compared in numerous studies, but long-term clinical outcomes are limited. Symptomatic patients with multivessel coronary artery disease (n = 1,829) were randomly assigned to initial treatment with PTCA or CABG and followed up for an average of 10.4 years.

Conclusions

The database contains a subset of the trial data and includes baseline characteristics and 10 year followup information on all 1,829 patients. Endpoints include subsequent revascularization, new myocardial infarction or death.

There was no significant long-term disadvantage regarding mortality or myocardial infarction associated with an initial strategy of PTCA compared with CABG. Among patients with treated diabetes, CABG conferred long-term survival benefit, whereas the 2 initial strategies were equivalent regarding survival for patients without diabetes.


Requests for Open BioLINCC Studies are submitted through this website. Click the Request button to begin.